-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

902.O2.6 902. Health Services and Quality—Lymphoid Malignancies: Time for Change: Health Care Delivery and Disparities

Symposia: Health Services and Quality—Lymphoid Malignancies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, Lymphoid Leukemias, ALL, Clinical Practice (Health Services and Quality), Lymphomas, non-Hodgkin lymphoma, epidemiology, elderly, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, B Cell lymphoma, Combination therapy, Clinical Research, Diversity, Equity, and Inclusion (DEI) , Diseases, Therapies, aggressive lymphoma, real-world evidence, Lymphoid Malignancies, registries, young adult , Study Population, Human, Minimal Residual Disease
Monday, December 12, 2022: 4:30 PM-6:00 PM
La Nouvelle Orleans Ballroom AB (Ernest N. Morial Convention Center)
Moderators:
Matthew C. Cheung, MD, MSc, Sunnybrook Odette Cancer Centre and Amy L Billett, MD, Dana-farber/Boston Children's Cancer and Blood Disorders Ctr
Disclosures:
No relevant conflicts of interest to declare.
4:30 PM

Hira S Mian, MD, MSc1, Martha L Louzada, MD, MSc2, Arleigh McCurdy, MD, BSc3, Ruthanne Cameron4*, Gregory R Pond, PhD, PStat1*, Tanya Wildes, MD, MSc5 and Darryl Leong, MBBS, MPH, PhD, FRACP, FESC6*

1Department of Oncology, McMaster University, Hamilton, ON, Canada
2University of Western Ontario, London Health Sciences Centre, London, ON, Canada
3Department of Medicine, Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada
4Juravinski Cancer Centre (Hamilton-CCO), Hamilton, ON, Canada
5University of Nebraska Medical Center, Omaha, NE
6McMaster University, Hamilton, ON, CAN

4:45 PM

Neha Korde, MD1, Benjamin Diamond, MD2, Miranda Burge3*, Hani Hassoun, MD3, Heather Landau, MD4, Malin Hultcrantz, MD, PhD3, Sham Mailankody, MBBS 4, Kylee H Maclachlan, MBBCh, PhD3, Urvi A Shah, MD3, Andriy Derkach, PhD5*, Saad Usmani, MD6, Ola Landgren, MD7 and Alexander Lesokhin, MD8

1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, NY
2Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
3Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
4Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
6Levine Cancer Institute, New York, NY
7Myeloma Division, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
8Memorial Sloan-Kettering Cancer Ctr., New York, NY

5:00 PM

Radhika Bansal, MBBS1*, Jonas Paludo, MD2, Matthew A. Hathcock, M.S.3*, Megan T Spychalla, P.A.-C.1*, Arushi Khurana, MBBS1, Paul J. Hampel, MD2, Urshila Durani, MD, MPH4, Hassan B. Alkhateeb, MD1*, David Dingli, MD, PhD1, Suzanne R. Hayman, MD1, Prashant Kapoor, MD5, Yucai Wang, MD, PhD2, Saad S. Kenderian, MD2, Moritz Binder, MD1, Taxiarchis Kourelis, MD1, Shaji K Kumar, MD5, Mithun V. Shah, MD, PhD1, Rahma M Warsame, MD5, N. Nora Nora Bennani, MD1, Morie A Gertz, MD6, Patrick B. Johnston, MD, PhD5, Stephen M. Ansell, MD, PhD1, Mustaqeem A. Siddiqui, M.D., M.B.A.1 and Yi Lin, MD, PhD5

1Division of Hematology, Mayo Clinic, Rochester, MN
2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
3Department of Biostatistics, Mayo Clinic, Rochester, MN
4Division of Hematology, Department of Internal Medicine, Mayo Clinic, Pasadena, CA
5Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
6Division of Hematology, Department of Internal Medicine, Mayo Clinic, ROCHESTER, MN

5:15 PM

Lori Muffly, MD, MS1, Ariadna Garcia2*, Katharine Miller, PhD2*, Theresa H.M. Keegan, PhD3 and Helen Parsons, PhD MPH4*

1Stanford University, Stanford, CA
2Quantitative Sciences Unit, Stanford University, Stanford, CA
3Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA
4Division of Health Policy and Management, University of Minnesota, Minneapolis

5:30 PM

Elisa Emanueli Cippitelli1*, Vincenza Innocenti, Nurse1*, Gioia De Angelis, MD1*, Silvia Bertelli, Nurse1*, Roberta Talucci, Nurse2*, Roberta Perazzini, Nurse1*, Roberta Burla, Nurse, Data Manager1*, Valentina Panichi3*, Giuseppe Topini3*, Ambra Di Veroli, MD1*, Alessia Fiorini, MD4*, Caterina Mercanti, MD1*, Fiammetta Natalino, MD1*, Caterina Stefanizzi, MD5*, Cinzia De Gregoris, MD1*, Michela Tarnani, MD1*, Marco Morucci, MD1*, Cristina Mastino, Data manager1*, Giulio Trapè, MD1*, Marco Montanaro, MD4*, Roberto Latagliata, MD1* and Silvia Ciambella, Nurse team chief1*

1Hematology, Belcolle Hospital, Viterbo, Italy
2Hematology Unit, Belcolle Hospital, Viterbo, Italy
3UOC Diagnostica Clinica, Laboratorio di Citofluorimetria, Belcolle Hospital, Viterbo, Italy
4Hematology, Belcolle Hospital, Viterbo, ITA
5Hematology, Belcolle Hospital, Viterbo, AL, ITA

5:45 PM

Christine I. Chen, MD1 and Jennifer A.H. Bell, PhD2,3*

1Princess Margaret Cancer Centre, Toronto, Canada
2Department of Clinical and Organizational Ethics, University Health Network, Toronto, ON, Canada
3University of Toronto, Toronto, ON, Canada

*signifies non-member of ASH